Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026)

Vanda Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $51.7 million for Q1 2026.

• In Q1 2026, Revenue rose 3.35% year-over-year to $51.7 million; the TTM figure through Mar 2026 stood at $217.8 million (up 8.16% YoY), while the FY2025 annual figure was $216.1 million, up 8.72% from the prior year.
• Revenue came in at $51.7 million for Q1 2026 at Vanda Pharmaceuticals, down from $57.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $65.3 million in Q3 2022 to a low of $38.8 million in Q3 2023.
• A 5-year average of $53.7 million and a median of $52.6 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 40.58% in 2023 and climbed 22.76% in 2024, its largest moves.
• Vanda Pharmaceuticals' Revenue stood at $64.5 million in 2022, then dropped by 29.79% to $45.3 million in 2023, then increased by 17.48% to $53.2 million in 2024, then advanced by 7.58% to $57.2 million in 2025, then decreased by 9.61% to $51.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $51.7 million, $57.2 million, and $56.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison